دورية
Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial
| العنوان: | Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial |
|---|---|
| المؤلفون: | Michels, Sebastian, Massutí, Bartomeu, Schildhaus, Hans-Ulrich, Franklin, Jeremy, Sebastian, Martin, Felip, Enriqueta, Grohé, Christian, Rodriguez-Abreu, Delvys, Abdulla, Diana S.Y., Bischoff, Helge, Brandts, Christian, Carcereny, Enric, Corral, Jesús, Dingemans, Anne-Marie C., Pereira, Eva, Fassunke, Jana, Fischer, Rieke N., Gardizi, Masyar, Heukamp, Lukas, Insa, Amelia, Kron, Anna, Menon, Roopika, Persigehl, Thorsten, Reck, Martin, Riedel, Richard, Rothschild, Sacha I., Scheel, Andreas H., Scheffler, Matthias, Schmalz, Petra, Smit, Egbert F., Limburg, Meike, Provencio, Mariano, Karachaliou, Niki, Merkelbach-Bruse, Sabine, Hellmich, Martin, Nogova, Lucia, Büttner, Reinhard, Rosell, Rafael, Wolf, Jürgen |
| المصدر: | Journal of Thoracic Oncology; July 2019, Vol. 14 Issue: 7 p1266-1276, 11p |
| مستخلص: | ROS1rearrangements are found in 1% of lung cancer patients. Therapeutic efficacy of crizotinib in this subset has been shown in early phase trials in the United States and East Asia. Here we present data on efficacy and safety of a prospective phase II trial evaluating crizotinib in European ROS1-positive patients (EUCROSS). |
| قاعدة البيانات: | Supplemental Index |
Full Text Finder | تدمد: | 15560864 15561380 |
|---|---|
| DOI: | 10.1016/j.jtho.2019.03.020 |